Long COVID Linked to Persistent Immune Response, Offering Potential for Biomarkers and Therapies
Millions worldwide continue to grapple with the long-term effects of COVID-19, commonly known as Long COVID. New research identifies persistently elevated levels of the immune protein interferon gamma (IFN-γ) as a potential biomarker for Long COVID fatigue and reveals an underlying immunological mechanism that could pave the way for targeted therapies.
Understanding the Link Between IFN-γ and Long COVID
The study, published in Science Advances, followed a cohort of Long COVID patients for over 2.5 years. Researchers found that initial SARS-CoV-2 infection triggers the production of IFN-γ, a natural immune response. While IFN-γ levels typically subside as the infection clears, they remained elevated in some patients for up to 31 months, correlating with ongoing symptoms.
Key Findings of the Research
- Persistent IFN-γ Levels: High levels of IFN-γ were found to persist in Long COVID patients, unlike those recovering from acute infection. Research indicates this release is T cell-mediated and dependent on antigen presentation by CD14+ cells.
- Correlation with Fatigue: The study specifically focused on fatigue, a common and debilitating symptom of Long COVID and found a strong association with sustained IFN-γ production.
- Cellular Source of IFN-γ: Researchers identified CD8+ T cells, in conjunction with CD14+ monocytes, as the primary source of the persistent IFN-γ release.
- Improvement with Symptom Resolution: Longitudinal follow-up showed that symptom improvement correlated with a decrease in IFN-γ production to baseline levels.
- Impact of Vaccination: Vaccination was associated with a significant decrease in IFN-γ levels in patients whose symptoms resolved, suggesting a potential role in clearing the persistent immune response.
Implications for Diagnosis and Treatment
Dr. Benjamin Krishna, a co-author of the study from the Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), stated, “We have found a potential mechanism underlying Long COVID which could represent a biomarker – that is, a tell-tale signature of the condition. We hope that this could help to pave the way to develop therapies and give some patients a firm diagnosis.”
The researchers suggest that identifying IFN-γ levels could help classify Long COVID into subtypes, allowing for more personalized treatment approaches. They too note that the symptoms associated with high IFN-γ levels – fatigue, fever, headache, muscle aches, and depression – are similar to those experienced by Long COVID patients.
Long COVID Statistics and Burden
Long COVID continues to be a significant public health concern. According to the Office for National Statistics (ONS), an estimated 1.9 million people in the UK alone (2.9% of the population) were experiencing self-reported Long COVID as of March 2023. Fatigue remains the most prevalent and debilitating symptom.
Future Research and Pandemic Preparedness
The Cambridge team emphasizes the importance of understanding Long COVID to prepare for future coronavirus pandemics. “Understanding what causes Long COVID now could give us a crucial head start,” Dr. Krishna added. While previous studies have explored microclotting as a potential cause, this research suggests that IFN-γ persistence plays a significant role.
Further research is needed to develop effective therapies targeting the persistent IFN-γ response and to refine diagnostic tools for Long COVID subtypes.
The post Long COVID: Persistent Interferon Gamma Linked to Fatigue & Potential Therapies appeared first on Archynewsy.